Hepion Pharmaceuticals and Pharma Two B have terminated a reverse merger agreement that was expected to close by the end of the year. The decision was mutual, meaning neither company will have to ...

“This reverse merger represents a US$452 million transaction at a deemed price of US$3.20 per share —a significant milestone that we believe will enhance market visibility while supporting our ...